Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval
Pfizer’s Braftovi received accelerated FDA approval in December as a first-line treatment for metastatic colorectal cancer with a particular genetic mutation. The pharma giant now says the drug has hit primary and secondary goals of its Phase 3 clinical trial.
